Intra-Cellular Therapies Inc [ITCI] stock is trading at $75.76, up 2.92%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ITCI shares have gain 3.94% over the last week, with a monthly amount glided 0.72%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Intra-Cellular Therapies Inc [NASDAQ: ITCI] stock has seen the most recent analyst activity on September 06, 2024, when Piper Sandler upgraded its rating to a Overweight and also boosted its price target to $92 from $68. Previously, Robert W. Baird started tracking the stock with Outperform rating on January 03, 2024, and set its price target to $83. On December 11, 2023, TD Cowen initiated with a Outperform rating and assigned a price target of $75 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $80 on April 20, 2023. Goldman downgraded its rating to a Neutral and reduced its price target to $49 on August 22, 2022. Mizuho started tracking with a Buy rating for this stock on July 07, 2022, and assigned it a price target of $74. In a note dated June 14, 2022, UBS initiated an Buy rating and provided a target price of $75 on this stock.
Intra-Cellular Therapies Inc [ITCI] stock has fluctuated between $45.50 and $84.89 over the past year. Currently, Wall Street analysts expect the stock to reach $94 within the next 12 months. Intra-Cellular Therapies Inc [NASDAQ: ITCI] shares were valued at $75.76 at the most recent close of the market. An investor can expect a potential return of 24.08% based on the average ITCI price forecast.
Analyzing the ITCI fundamentals
Intra-Cellular Therapies Inc [NASDAQ:ITCI] reported sales of 564.53M for the trailing twelve months, which represents a growth of 45.67%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -0.11 and Total Capital is -0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 74.25 points at the first support level, and at 72.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 76.73, and for the 2nd resistance point, it is at 77.70.
Ratios To Look Out For
For context, Intra-Cellular Therapies Inc’s Current Ratio is 7.81. As well, the Quick Ratio is 7.69, while the Cash Ratio is 4.3. Considering the valuation of this stock, the price to sales ratio is 14.18, the price to book ratio is 6.99.
Transactions by insiders
Recent insider trading involved ALEXANDRIA VENTURE INVESTMENTS, Director, that happened on Sep 06 ’24 when 25000.0 shares were purchased. Chairman and CEO, Mates Sharon completed a deal on Aug 29 ’24 to sell 35604.0 shares. Meanwhile, Chairman and CEO Mates Sharon sold 34396.0 shares on Aug 30 ’24.
